Concepedia

Author

Rachel Wuerstlein

Ludwig-Maximilians-Universität MünchenORCID

Also Known As

Bruno Vincenzi, Clara Maluquer, F. Stoeblen, Franziska Henze, M. Carmen Carmona-Garcia, R Wuerstlein, R. Wuerstlein, R., Wuerstlein, Rachel Wuerstlein, Rachel Würstlein

471

Publications

5.6K

Citations

37

H-Index

54

Concepts

All Affiliations

Ludwig-Maximilians-Universität MünchenKliniken Essen-MitteCharité - Universitätsmedizin BerlinMedizinische Hochschule HannoverLMU Klinikum
RW

About

Rachel Wuerstlein is an author at Ludwig-Maximilians-Universität München specializing in medicine, breast cancer, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

21

38

1.4K

2

Health Sciences

12

13

319

3

Nursing

5

5

151

4

Public Health

2

2

36

5

Engineering

1

1

30

Rachel Wuerstlein

×

88

Publications

4.1K

Citations

33

H-Index

YearCitations

West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment

Oleg Gluz, Ulrike Nitz, Matthias Christgen,

Journal of Clinical Oncology

2016

357

Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial☆

Filippo Montemurro, Suzette Delaloge, Carlos H. Barrios,

Annals of Oncology

2020

328

Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial

Ulrike Nitz, Oleg Gluz, Matthias Christgen,

Breast Cancer Research and Treatment

2017

183

Central venous access in oncology: ESMO Clinical Practice Guidelines

Berta Sousa, Jenny Furlanetto, Margaret Hutka,

Annals of Oncology

2015

179

De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR− phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel

Ulrike Nitz, Oleg Gluz, Matthias Christgen,

Annals of Oncology

2017

162

West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer

Ulrike Nitz, Oleg Gluz, Michael Clemens,

Journal of Clinical Oncology

2019

144

De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)–Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor–Positive Phase II Randomized Trial—Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET

Nadia Harbeck, Oleg Gluz, Matthias Christgen,

Journal of Clinical Oncology

2017

143

Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results

Oleg Gluz, Ulrike Nitz, Cornelia Liedtke,

JNCI Journal of the National Cancer Institute

2017

122

Chemotherapy and Post-traumatic Stress in the Causation of Cognitive Dysfunction in Breast Cancer Patients

Kerstin Hermelink, Markus Bühner, Philipp Sckopke,

JNCI Journal of the National Cancer Institute

2017

116

Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: Primary results from the KAMILLA study cohort 1

Filippo Montemurro, Antonio Antón, Rachel Wuerstlein,

European Journal of Cancer

2019

100

Page 1